Deltex Medical (LON:DEMG) has added two more hospitals to its US client list after evaluations of its blood flow monitoring systems.
The two additions are part of a network of nine hospitals and both chose Deltex’s oesophageal Doppler monitoring systems after clinical trials.
A procurement agreement has also been put in place that will allow other hospitals in the network to take up ODM more rapidly.
Initial probe purchase requirements are for 40 and 50 probes per month respectively. Two new clinical trainers will be recruited to help boost that number to over 100 per month at each site.
Deltex now has 17 US hospitals using ODM, with 11 of these added this year.
Ewan Phillips, Deltex's chief executive, the US eventually will become the company’s key territory as adoption rates there are outstripping its other areas.
“Deltex Medical is now over half way towards our current goal of 30 US hospitals on our platform programme by mid-2016."